Free Trial

Oruka Therapeutics Q3 2023 Earnings Report

Oruka Therapeutics logo
$12.67 +0.60 (+4.97%)
As of 04:00 PM Eastern

Oruka Therapeutics EPS Results

Actual EPS
-$14.40
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Oruka Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Oruka Therapeutics Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Oruka Therapeutics Earnings Headlines

Brokerages Set Oruka Therapeutics, Inc. (NASDAQ:ORKA) PT at $43.17
Is this the pin that pops the bubble?
CEO Jensen Huang does not want you knowing this dirty little secret about Nvidia… In fact, any day now we’re expecting a cease and desist from Nvidia’s lawyers. Go here now before it’s too late to find out why Nvidia shares are slumping so hard.
See More Oruka Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oruka Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oruka Therapeutics and other key companies, straight to your email.

About Oruka Therapeutics

Oruka Therapeutics (NASDAQ:ORKA) is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

View Oruka Therapeutics Profile

More Earnings Resources from MarketBeat